Acute-phase protein levels and QoL by SF36 before and during treatment with anakinra. (A) Acute-phase protein CRP levels measured before administration of treatment (median baseline, 67 mg/L [range, 18-257 mg/L]) and while on treatment (median baseline, 5 mg/L [range, 3-10 mg/L]) showed a significant reduction (P < .0001). (B) Patients were surveyed before starting anakinra, and while on treatment of 3 to 4 months. A comparison of the mean scores in each domain before and on treatment was statistically significant (Mann Whitney P = .0003); clinically meaningful improvements, to well above that of healthy age-matched US controls (normalized to 50), were seen in all domains (a change of 10 points or more is considered clinically significant). BP, bodily pain; GH, general health; MH, mental health; PF, physical function; RE, role emotional; RP, role physical; SF, social function; VT, vitality.